Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma.

Détails

ID Serval
serval:BIB_7490C8DDD443
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma.
Périodique
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
Auteur(s)
Zhao Y., Duran R., Chapiro J., Sohn J.H., Sahu S., Fleckenstein F., Smolka S., Pawlik T.M., Schernthaner R., Zhao L., Lee H., He S., Lin M., Geschwind J.F.
ISSN
1873-4626 (Electronic)
ISSN-L
1091-255X
Statut éditorial
Publié
Date de publication
12/2016
Volume
20
Numéro
12
Pages
2002-2009
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
It remains controversial whether transarterial chemoembolization (TACE) should be performed in patients with advanced-stage hepatocellular carcinoma (HCC). The present large retrospective cohort study aimed to define the survival outcome following TACE of advanced HCC and to identify the prognostic factors. Five hundred eight patients with Barcelona Clinic Liver Cancer (BCLC) C-stage HCC, Child-Pugh A/B who were treated with TACE between November 1998 and December 2013 were identified. There was no significant difference in overall survival (OS) between patients with Eastern Cooperative Oncology Group (ECOG) 0 and those with ECOG ≥1 (10.5 months vs. 11.9 months, P = 0.87). The median OS of patients without portal vein tumor thrombosis (PVTT) was longer than that of patients with PVTT (16.9 vs. 6.1 months, P < 0.001). Child-Pugh B class, PVTT, extrahepatic metastasis, tumor size ≥5 cm, number of tumors ≥3, and alpha-fetoprotein ≥400 ng/dL were significantly associated with decreased survival and were used for determining the risk scores. All patients were divided into two groups (low-risk and high-risk groups) according to the cutoff value of 6.5 for risk scores. The patients with a value <6.5 (low-risk group) had significantly longer survival than those with >6.5 (high-risk group) (24.1 vs. 7.5 months, respectively; P < 0.001). TACE is an effective therapy for select patients with advanced stage HCC and may provide equal or improved survival as compared with reported outcomes with sorafenib. The results highlight the need for a differentiated approach to therapeutic recommendations for patients with BCLC C.

Pubmed
Création de la notice
07/12/2016 18:17
Dernière modification de la notice
03/03/2018 18:21
Données d'usage